| T vs. C | ipilimumab alone | nivolumab alone | nivolumab plus ipilimumab | ipilimumab followed by nivolumab | Standard of Care (SoC) | nivolumab followed by ipilimumab | tremelimumab | relatlimab plus nivolumab |
| ipilimumab alone | --- | NA | NA | NA | NA | NA | NA | NA |
| nivolumab alone | NA | --- | NA | NA | NA | NA | NA | NA |
| nivolumab plus ipilimumab | NA | NA | --- | NA | NA | NA | NA | NA |
| ipilimumab followed by nivolumab | NA | NA | NA | --- | NA | NA | NA | NA |
| Standard of Care (SoC) | NA | NA | NA | NA | --- | NA | NA | NA |
| nivolumab followed by ipilimumab | NA | NA | NA | NA | NA | --- | NA | NA |
| tremelimumab | NA | NA | NA | NA | NA | NA | --- | NA |
| relatlimab plus nivolumab | NA | NA | NA | NA | NA | NA | NA | --- |
pathologies: 68 - treatments: 980 result logic
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
